Company type | Subsidiary of Pfizer |
---|---|
Industry | Pharmaceutical |
Founded | 1888 | (as G. D. Searle & Company)
Founder | Gideon Daniel Searle |
Headquarters | New York City, United States |
Products | Pharmaceutical products |
Website | searlecompany |
G.D. Searle, LLC is a wholly owned subsidiary of Pfizer. [1] It is currently a trademark company and subsidiary of Pfizer, operating in more than 43 countries. It also operates as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle). Searle is most notable for having developed the first female birth control pill, [2] and the artificial sweetener NutraSweet. Searle also developed the drug Lomotil, an antidiarrheal medication. One notable alumnus of Searle is Donald Rumsfeld, the Secretary of Defense for George W. Bush in the 2000s. Prior to its 1985 merger with Monsanto, Searle was a company mainly focusing on life sciences, specifically pharmaceuticals, agriculture, and animal health.
In 1888 , Gideon Daniel Searle founded Searle in Omaha, Nebraska. [3] The company incorporated in 1908 and established headquarters in Skokie, Illinois in 1941. [3]
Daniel C. Searle served as the chief executive officer and president of G. D. Searle & Co from 1970 to 1977 and initially led efforts to gain FDA approval of the artificial sweetener aspartame. [4] [5]
Between 1977 and 1985, Donald Rumsfeld was CEO, and then president, of Searle. [6] [7] In 1985, he negotiated the acquisition of Searle by Monsanto Corporation. [8]
In 1993, a team of researchers at Searle Research and Development filed a patent application for celecoxib, [9] which Searle developed and which became the first selective COX-2 inhibitor to be approved by the FDA on December 31, 1998. [10] Control of this blockbuster drug was often mentioned as a key reason for Pfizer's acquisition of Pharmacia. [11]
The company manufactures prescription drugs and nuclear medicine imaging equipment. Searle is known for its release of Enovid, the first commercial oral contraceptive, in 1960. [12]
In 1996, the FDA removed all restrictions on the use of aspartame, which enabled its use in heated and baked goods. G. D. Searle's patent on aspartame was extended in 1981 and ultimately expired in December 1992. [13]
Aspartame is an artificial non-saccharide sweetener 200 times sweeter than sucrose and is commonly used as a sugar substitute in foods and beverages. It is a methyl ester of the aspartic acid/phenylalanine dipeptide with brand names NutraSweet, Equal, and Canderel. Aspartame was approved by the US Food and Drug Administration (FDA) in 1974, and then again in 1981, after approval was revoked in 1980.
A sugar substitute is a food additive that provides a sweetness like that of sugar while containing significantly less food energy than sugar-based sweeteners, making it a zero-calorie or low-calorie sweetener. Artificial sweeteners may be derived through manufacturing of plant extracts or processed by chemical synthesis. Sugar substitute products are commercially available in various forms, such as small pills, powders, and packets.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).
The Monsanto Company was an American agrochemical and agricultural biotechnology corporation founded in 1901 and headquartered in Creve Coeur, Missouri. Monsanto's best-known product is Roundup, a glyphosate-based herbicide, developed in the 1970s. Later, the company became a major producer of genetically engineered crops. In 2018, the company ranked 199th on the Fortune 500 of the largest United States corporations by revenue.
Acesulfame potassium, also known as acesulfame K or Ace K, is a synthetic calorie-free sugar substitute often marketed under the trade names Sunett and Sweet One. In the European Union, it is known under the E number E950. It was discovered accidentally in 1967 by German chemist Karl Clauss at Hoechst AG. Acesulfame potassium is the potassium salt of 6-methyl-1,2,3-oxathiazine-4(3H)-one 2,2-dioxide. It is a white crystalline powder with molecular formula C
4H
4KNO
4S and a molecular weight of 201.24 g/mol.
The pharmaceutical industry is an industry involved in medicine that discovers, develops, produces, and markets pharmaceutical goods for use as drugs that function by being administered to patients using such medications with the goal of curing and/or preventing disease. Pharmaceutical companies may deal in "generic" medications and medical devices without the involvement of intellectual property, in "brand" materials is specifically tied to a given company's history, or in both within different contexts. The industry's has various subdivisions are all subject to a variety of laws and regulations that govern entire financial processes including the patenting, efficacy testing, safety evaluation, and marketing of these drugs. The global pharmaceuticals market produced treatments worth $1,228.45 billion in 2020, in total, and this showed a compound annual growth rate (CAGR) of 1.8% given the results of recent events.
Celecoxib, sold under the brand name Celebrex among others, is a COX-2 inhibitor and nonsteroidal anti-inflammatory drug (NSAID). It is used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, painful menstruation, and juvenile rheumatoid arthritis. It may also be used to decrease the risk of colorectal adenomas in people with familial adenomatous polyposis. It is taken by mouth. Benefits are typically seen within an hour.
Valdecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is a selective cyclooxygenase-2 inhibitor. It was patented in 1995.
The NutraSweet Company is an American nutrient company that produces and markets NutraSweet Neotame, their trademarked brand name for the high-intensity sweetener neotame.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995. Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.
Alitame is an aspartic acid-containing dipeptide sweetener. It was developed by Pfizer in the early 1980s and currently marketed in some countries under the brand name Aclame. Most dipeptides are not sweet, but the unexpected discovery of aspartame in 1965 led to a search for similar compounds that shared its sweetness. Alitame is one such second-generation dipeptide sweetener. Neotame, developed by the owners of the NutraSweet brand, is another.
Equal is an American brand of artificial sweetener containing aspartame, acesulfame potassium, dextrose and maltodextrin. It is marketed as a tabletop sweetener by Merisant, a global corporation which also previously owned the well-known NutraSweet brand when it was a subsidiary of Monsanto and which has headquarters in Chicago, Illinois, Switzerland, Mexico, and Singapore. In French Canada, Equal is known as "Égal".
The artificial sweetener aspartame has been the subject of several controversies since its initial approval by the U.S. Food and Drug Administration (FDA) in 1974. The FDA approval of aspartame was highly contested, beginning with suspicions of its involvement in brain cancer, alleging that the quality of the initial research supporting its safety was inadequate and flawed, and that conflicts of interest marred the 1981 approval of aspartame, previously evaluated by two FDA panels that concluded to keep the approval on hold before further investigation. In 1987, the U.S. Government Accountability Office concluded that the food additive approval process had been followed properly for aspartame. The irregularities fueled a conspiracy theory, which the "Nancy Markle" email hoax circulated, along with claims—counter to the weight of medical evidence—that numerous health conditions are caused by the consumption of aspartame in normal doses.
Robert B. Shapiro is an American businessman and attorney who has worked extensively with the biochemical corporations G. D. Searle & Company and Monsanto. Before working in this sector he was Vice-President and legal counsel at General Instrument from 1972 to 1979. His father, Moses, was Chairman of this company from 1969 to 1975.
SUGEN (Sugen) was a drug discovery company focused on development of protein kinase inhibitors. It was founded in 1991, and shut down in 2003, after developing the pioneering kinase inhibitor drug sunitinib (Sutent).
Repros Therapeutics Inc. (Nasdaq: RPRX), was a US-based development stage biopharmaceutical company headquartered in The Woodlands, Texas. Founded in 1987 as Zonagen, it focused on the development of oral small molecule drugs to address major unmet medical needs in male and female health. Joseph S. Podolski was the CEO of this company.
Networked Robotics Corporation is an American scientific automation company that designs and manufactures electronic devices that monitor scientific instruments, scientific processes, and environmental conditions via the internet.
Wyeth was a pharmaceutical company until it was purchased by Pfizer in 2009. The company was founded in Philadelphia, Pennsylvania, in 1860 as John Wyeth and Brother. Its headquarters moved to Collegeville, Pennsylvania, and Madison, New Jersey, before its headquarters were consolidated with Pfizer's in New York City after the 2009 merger.
Daniel C. Searle was an American business executive and philanthropist. He served as the Chief Executive Officer and President of G. D. Searle & Co from 1970 to 1977, and as its Chairman from 1977 until its merger with Monsanto in 1985.. He established the Searle Freedom Trust to promote free market economics.